Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report

Satoshi Komiyama(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Katsuaki Ogushi(Yokohama City University Medical Center), Makoto Chuma(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Masako Otani(Mita Hospital), Sawako Chiba(National Hospital Organization), Masayuki Nakano(Nihon University), Yoshiaki Inayama(Yokohama City University Medical Center), Reiko Tanaka(Imperial College London)
Diagnostics
August 1, 2021
10.3390/diagnostics11081394
Cited by 2

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283